DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0328259 A1 SHANLER Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0328259 A1 SHANLER Et Al US 2015 0328259A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0328259 A1 SHANLER et al. (43) Pub. Date: Nov. 19, 2015 (54) PEROXIDE FORMULATIONS AND Publication Classification METHODS AND APPLICATORS FORUSING THE SAME (51) Int. Cl. A633/40 (2006.01) (71) Applicant: ACLARIS THERAPEUTICS, INC., A619/00 (2006.01) Malvern, PA (US) A6M 35/00 (2006.01) (72) Inventors: Stuart D. SHANLER, Malvern, PA A647/10 (2006.01) (US); Christopher POWALA, Radnor, (52) U.S. Cl. PA (US); Christopher PHILLIPS, CPC ................. A61K 33/40 (2013.01); A61K 47/10 Doylestown, PA (US); Brian BEGER, (2013.01); A61 K9/0014 (2013.01); A61M Newtown, PA (US); Charles Rodney 35/003 (2013.01); A61M 2205/7545 (2013.01) GREENAWAY EVANS, Surrey (GB); Sian Tiong LIM, Surrey (GB); Marc Barry BROWN, Watford Hertfordshire (57) ABSTRACT (GB); Michael A. BOTTA, Ridge, NY (US); Thomas NAGLER, Greenlawn, NY (US) Embodiments are directed to a stable composition compris ing stabilized hydrogen peroxide and 2-propanol and appli (21) Appl. No.: 14/692,665 cators configured to store, dispense, and apply Such stable (22) Filed: Apr. 21, 2015 compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, mollus Related U.S. Application Data cum contagiosum, acrochordons, seborrheic keratosis, or a (60) Provisional application No. 61/982.217, filed on Apr. combination thereof. Some embodiments also describe take 21, 2014, provisional application No. 62/085,466, home compositions, in office compositions, over-the-counter filed on Nov. 28, 2014. compositions, and kits for the use of Such compositions. 1300 / 1335 1340 1305 3. Patent Application Publication Nov. 19, 2015 Sheet 1 of 20 US 2015/0328259 A1 $333333 : MS-8i x333.8 :::::::::838: 888 FGURE Patent Application Publication Nov. 19, 2015 Sheet 2 of 20 US 2015/0328259 A1 83.38 33.8 23333.33 : 8 :38.8 & 83 : R 2 Patent Application Publication Nov. 19, 2015 Sheet 3 of 20 US 2015/0328259 A1 38883 : & 2.3 x 3.33 &.33 xxx8to: 2333333 1833 88: FGRE3 Patent Application Publication Nov. 19, 2015 Sheet 4 of 20 US 2015/0328259 A1 - - - - - - 3.33:3: 3-x8358: . .388: 32-3:3:38; 4383 . 3. : s : 33}: 83 : 3: 8. : s: 3883- : 38.3 : : X. 8.S. 2333 :: k : 28:8. 38: 83 : 2 a :8 8 8: &8 & 3::::::::::::::::::::::::::::::::x: 8% &; FGRE a Patent Application Publication Nov. 19, 2015 Sheet 5 of 20 US 2015/0328259 A1 388 : 38883. 38883 : ::::::: 888) : i 3. &: & 8:33:::::::::::::::::::::::iia: % six8; FGRES Patent Application Publication Nov. 19, 2015 Sheet 6 of 20 US 2015/0328259 A1 383 : *x x2-issip3:x: 8 . 8 38 i. 8 38 2: P:8:338c: ::::::::::::::::::::::::::::::::8: FGRE 6 Patent Application Publication Patent Application Publication Nov. 19, 2015 Sheet 8 of 20 US 2015/0328259 A1 Patent Application Publication US 2015/0328259 A1 Patent Application Publication Nov. 19, 2015 Sheet 10 of 20 US 2015/0328259 A1 ... is: xx.38 ki -8-838: -&-2.S. 888 &S-38sk wa-S 8: ss. +x-Siss S-S-3.3 is ski 2- : six Cois S. -k .38 ski 8.338 Ski 3-88 ski; 3-2. A skis - 88s 2.38::::: 328 ski; -- is: 3.8 skis .22.SS & - 23 cc; it ski: 43.38 : :s CGURE O Patent Application Publication Nov. 19, 2015 Sheet 11 of 20 US 2015/0328259 A1 s 's & FIGURE 11 Patent Application Publication Nov. 19, 2015 Sheet 12 of 20 US 2015/0328259 A1 N3. 3. s s Patent Application Publication Nov. 19, 2015 Sheet 13 of 20 US 2015/0328259 A1 / Patent Application Publication Nov. 19, 2015 Sheet 14 of 20 US 2015/0328259 A1 Patent Application Publication Nov. 19, 2015 Sheet 15 of 20 US 2015/0328259 A1 Patent Application Publication Nov. 19, 2015 Sheet 16 of 20 US 2015/0328259 A1 ~~~~~~~. &~~~~~~~~~~~~~* Patent Application Publication Nov. 19, 2015 Sheet 17 of 20 US 2015/0328259 A1 Patent Application Publication Nov. 19, 2015 Sheet 18 of 20 US 2015/0328259 A1 &x & xxx-xxx xxx: ---. S--- -3----. -------- 888. 8:8: $8x88: 8888:x: F.G. 17A Patent Application Publication Nov. 19, 2015 Sheet 19 of 20 US 2015/0328259 A1 s s Patent Application Publication Nov. 19, 2015 Sheet 20 of 20 US 2015/0328259 A1 US 2015/0328259 A1 Nov. 19, 2015 PEROXDE FORMULATIONS AND fying agent is an agent stable in compositions comprising METHODS AND APPLICATORS FORUSING concentrations of hydrogen peroxide disclosed in embodi THE SAME ments herein. In some embodiments, the Surface tension modifying agent is in a quantity Sufficient to enhance the BRIEF SUMMARY therapeutic efficacy of the composition. In some embodi 0001 Embodiments in this disclosure are directed to a ments, the Surface tension modifying agent is in a quantity composition comprising hydrogen peroxide and an alcohol. Sufficient to modify the Surface tension while maintaining In some embodiments, the hydrogen peroxide is stabilized stability of the composition Sufficient for use as a commer hydrogen peroxide. In some embodiments, the hydrogen per cially viable formulation. In some embodiments, the surface oxide may be a standard grade, food grade, chemical synthe tension modifying agent is an alcohol. In some embodiments, sis grade, semiconductor grade, high-test hydrogen peroxide the Surface tension modifying agent is 2-propanol. grade, antimicrobial grade, drinking watergrade, pharmaceu 0005 Embodiments herein also describe a method of tical grade or cosmetic grade hydrogen peroxide. In some treating a skin condition comprising administering a compo embodiments, the alcohol may be selected from a primary sition having up to about 50% hydrogen peroxide and an alcohol, a secondary alcohol, a tertiary alcohol, or a combi alcohol to a subject in need thereof. The skin condition may nation thereof. In some embodiments, the alcohol may be be a virally induced or non-virally induced cutaneous growth selected from 2-propanol, methanol, butanol. 1-propanol, or proliferation. The skin condition may be a benign neo pentanol, hexanol, octanol, nonanol, decanol. 2-pentanol, plasm, premalignancy or malignancy. The skin condition may 2-butanol, benzyl alcohol, ethanol, an isomer thereof, or a be an inflammatory condition. The skin condition may be a combination thereof. In some embodiments, the hydrogen hyperproliferative condition. The skin condition may be peroxide is in an amount up to about 50% of the composition. aging including intrinsic (e.g., chronological) and extrinsic In some embodiments the alcohol is in a quantity Sufficient to changes (e.g., photoaging, ultraViolet light induced changes). decrease the Surface tension of the composition. In some pigmentary changes, fine lines and rhytides. In some embodi embodiments, the alcohol is in an amount up to about 5% of ments, the skin condition may be selected from Human Pap the composition. In some embodiments, the composition is a illoma Virus induced lesions e.g., warts, common warts, pal Solution. In some embodiments, the composition is a gel moplantar warts, flat warts, recurrent warts, recalcitrant formulation. In some embodiments, the composition com warts, treatment naive warts, epidermodysplasia Verrucifor prises two or more separate components that may be admixed mis related warts, anogenital warts, condyloma accumina before, at, or near the time of use. tum, cervical dysplasias or neoplasias, e.g., cervical intraepi 0002 Some embodiments are directed to a topical com thelial neoplasia (CIN); Herpesvirus related lesions including position comprising up to about 50% hydrogen peroxide and those induced by HHV-1 (HSV-1), HHV-2 (HSV-2), HHV-3 up to 5% 2-propanol. In some embodiments, the hydrogen (varicella-Zoster virus) e.g., chicken pox, Herpes Zoster, peroxide is a stabilized hydrogen peroxide. In some embodi shingles; Poxvirus induced lesions e.g., molluscum contagio ments, the topical composition further includes a stabilizer. Sum, orf callus, cutaneous horns, corns, acrochordons, The stabilizer may be selected from stannate, sodium pyro fibroepithelial polyps, prurigo nodularis, actinic keratoses, phosphate, organophosphonate, nitrate, phosphoric acid, col squamous cell carcinoma, squamous cell carcinoma in situ, loidal silicate, any stabilizer known in the art, or a combina keratoacanthoma, basal cell carcinoma, cutaneous lympho tion thereof. In some embodiments, the 2-propanol is in an mas and benign lymphocytic infiltrates & hyperplasias of the amount Sufficient to decrease the Surface tension while mini skin, clear cell acanthoma, large cell acanthoma, epider mizing spread of the composition onto non-targeted skin molytic acanthoma, porokeratosis, hyperkeratosis, keratosis when applied to a targeted lesion. The composition may be pilaris lichenoid keratosis, acanthosis, acanthosis nigricans, stable for at least two years at 5°C., at least one year at 30°C., confluent and reticulated papillomatosis, nevi, including e.g., at least 6 months at 40°C., or a combination thereof. dermal nevi, epidermal nevi, compound nevi, ILVEN (in 0003. In some embodiments, the topical composition flammatory linear Verrucous epidermal nevi), nevus Seba comprises about 45% stabilized cosmetic-grade hydrogen ceous, nevus comedonicus, and the like; acne, e.g., come peroxide and about 5% 2-propanol, and wherein the topical donal acne, inflammatory acne, papular acne, pustular acne, composition has a surface tension of about 42 mNim-1 to cystic acne; cysts, e.g., epidermoid cysts, milia, trichilemmal about 55 mNim-1 at 37°C. In some embodiments, the topical cysts, follicular cysts, proliferating cysts, dermoid cysts, composition comprises about 40% stabilized cosmetic-grade pilonidal cysts, apocrine cysts, eccrine cysts, sebaceous cysts, hydrogen
Load more

Recommended publications
  • The Tamilnadu Dr. M.G.R. Medical University Chennai, Tamil Nadu
    CLINICO-PATHOLOGICAL STUDY OF SKIN SURFACE EPIDERMAL AND APPENDAGEAL TUMOURS Dissertation Submitted in partial fulfillment of university regulations for M.D. DEGREE IN DERMATOLOGY, VENEREOLOGY AND LEPROSY BRANCH XII – A THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY CHENNAI, TAMIL NADU SEPTEMBER 2006 CERTIFICATE This is to certify that this Dissertation entitled “CLINICO-PATHOLOGICAL STUDY OF SKIN SURFACE EPIDERMAL AND APPENDAGEAL TUMOURS” is a bonafide work done by DR.G.BALAJI, Postgraduate student of Department of Dermatology, Leprosy and Institute of STD, Madras Medical College and Government General Hospital, Chennai – 3 for the award of Degree of M.D.( Dermatology, Venereology and Leprosy ) Branch XII – A during the academic year of 2003-2006. This work has not previously formed in the basis for the award of any degree or diploma. Prof. Dr. B. Parveen, MD., DD., Professor & Head, Dept. of Dermatology and Leprosy, Madras Medical College & Govt. General Hospital, Chennai – 3. Prof. Dr. Kalavathy Ponniraivan, MD., The Dean Madras Medical College & Govt. General Hospital, Chennai – 3. SPECIAL ACKNOWLEDGEMENT I sincerely thank Prof. Dr. Kalavathy Ponniraivan, MD., Dean, Madras Medical College & Govt. General Hospital, Chennai – 3, for granting me permission to use the resources of this institution for my study. ACKNOWLEDGEMENT I sincerely thank Prof. B.Parveen MD.,DD, Professor and Head of Department of Dermatology for her invaluable guidance and encouragement for the successful completion of this study. I express my heart felt gratitude to Dr.N.Gomathy MD.,DD, former Head of department of Dermatology who was instrumental in the initiation of this project, giving constant guidance throughout my work.
    [Show full text]
  • Common Skin Tumors
    Topic Common Benign epidermal tumors Skin cyst and adnexal neoplasms skin tumors Other common skin tumor Common skin malignancy สมศกดั ิ์ ตนรั ตนากรั 26/02/2015 Seborrheic keratoses Benign Epidermal Tumors very common brown macules, papules, plaques, Seborrheic keratosis or polypoid lesions Dermatosis papulosa nigra over 40 y. Stucco keratosis increase number with age Inverted follicular keratosis Acrokeratosis verruciformis verrucous or 'stuck-on' the Clear cell acanthoma skin Large cell acanthoma predilection for face, neck, Porokeratosis and trunk Epidermal nevus Inflammatory linear verrucous epidermal nevus occur anywhere except Nevus comedonicus mucous membranes, palms, Epidermolytic acanthoma or soles Flegel’s disease sign of Leser-Trélat Cutaneous horn Lichenoid keratosis Acanthosis nigricans Confluent and reticulated papillomatosis Warty dyskeratoma Clinicopathologic Variants Common Seborrheic Keratosis Dermatosis Papulosa Nigra Skin Tags Irritated Seborrheic Keratosis Stucco Keratosis Reticulated Seborrheic Keratosis Clonal Seborrheic Keratoses Seborrheic Keratosis With Squamous Atypia Melanoacanthoma Leser-Trelat sign 1 Dermatosis papulosa nigra Seborrheic keratosis Skin tags Irritated Seborrheic Keratosis Stucco keratoses Epidermal nevi Multiple gray–white keratotic papules on ankle and benign hamartoma of epidermis and dorsal foot. papillary dermis onset usually within the first year of life asymptomatic well-circumscribed, hyperpigmented, papillomatous papules or plaques in a linear
    [Show full text]
  • WO 2015/164427 Al 29 October 2015 (29.10.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/164427 Al 29 October 2015 (29.10.2015) P O P C T (51) International Patent Classification: 11961 (US). NAGLER, Thomas; 1 Harborview Avenue, A61K 8/00 (2006.01) Greenlawn, New York 11740 (US). (21) International Application Number: (74) Agents: STAKLEFF, N. Nicole et al; Pepper Hamilton PCT/US20 15/026948 LLP, Suite 5000, 500 Grant Street, Pittsburgh, Pennsylvania 152 19-2507 (US). (22) International Filing Date: 2 1 April 2015 (21 .04.2015) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 61/982,217 2 1 April 2014 (21.04.2014) US KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 62/085,466 28 November 2014 (28. 11.2014) US MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicant: ACLARIS THERAPEUTICS, INC. (heir of PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, the deceased inventor) [US/US]; 101 Lindenwood Drive, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, Malvern, Pennsylvania 19355 (US).
    [Show full text]
  • Chapter 119 Appendage Tumors and Hamartomas of the Skin
    11. Stambolic V et al: Negative regulation of PKB/Akt- Chapter 119 dependent cell survival by the tumor suppressor Appendage Tumors PTEN. Cell 95:29, 1998 12. Ponti G et al: Value of MLH1 and MSH2 mutations and Hamartomas of in the appearance of Muir-Torre syndrome phe- notype in HNPCC patients presenting sebaceous the Skin gland tumors or keratoacanthomas. J Invest Dermatol 126:2302-2307, 2006 Divya Srivastava & R. Stan Taylor 13. Thiboutot D: Regulation of human sebaceous glands. J Invest Dermatol 123:1-12, 2004 14. James WD, Berger TG, Elston DM: Andrews’ Dis- eases of the Skin: Clinical Dermatology. Philadel- phia, Elsevier Health Sciences, 2005 15. Troy JL, Ackerman AB. Sebaceoma. A distinctive benign neoplasm of adnexal epithelium differen- tiating toward sebaceous cells. Am J Dermatopa- REFERENCES thol 6:7-13, 1984 16. Jadassohn J. Bemerkuger zur histologieder sys- tematisirten naevi and ueber “Talgdrusen-navi”. 1. Requena L et al: Neoplasms with Apocrine Differ- Arch Derm Syphilol 33:355-394, 1895 entiation. Philadelphia, Lippincott-Raven, Ardor 17. Carlson JA et al: Epidermodysplasia verruciformis- Scribendi, 1997 associated and genital-mucosal high-risk human 2. Steffen C, Ackerman AB: Neoplasms with Se- papillomavirus DNA are prevalent in nevus seba- baceous Differentiation. Philadelphia, Lea and ceus of Jadassohn. J Am Acad Dermatol 59:279-94, Febiger, 1994 2008 3. Ackerman AB et al: Neoplasms with Follicular Dif- 18. Happle R, Konig A: Familial nevus sebaceus may ferentiation. New York, Ardor Scribendi, 2001 be explained by paradominant transmission. Br J Dermatol 141:377, 1999 4. Ahmed TS, Del Priore J, Seykora J: Tumors of the Epidermal Appendages in Lever’s Histopathology, 19.
    [Show full text]
  • Skin Adnexal Tumors – Still a Pandora’S Box
    ORIGINAL RESEARCH PAPER Volume : 6 | Issue : 8 | August 2016 | ISSN - 2249-555X | IF : 3.919 | IC Value : 74.50 ORIGINAL RESEARCH PAPER Medical Science Volume : 6 | Issue : 8 | August 2016 | ISSN - 2249-555X | IF : 3.919 | IC Value : 74.50 Skin Adnexal Tumors – Still a Pandora’s Box KEYWORDS adnexal neoplasm, eccrine, apocrine * P.Umarani C.Swathi K.Rama murthy Assistant Professor, Department Assistant Professor, Department Professor & HOD, Department of Pathology,Alluri Sitarama Raju of Pathology,Alluri Sitarama Raju of Pathology,Alluri Sitarama Raju Academy of Medical Sciences, Academy of Medical Sciences, Academy of Medical Sciences, Eluru – 534005,W.G.Dist, Andhra Eluru – 534005,W.G.Dist, Andhra Eluru – 534005,W.G.Dist, Andhra Pradesh. * Corresponding Author Pradesh. Pradesh. ABSTRACT Evaluation of skin biopsies with special emphasis on adnexal neoplasms in regards to incidence, mor- phological sub-types and also few prognostically indeterminate mimics in adnexal neoplasms.In a 3year retrospective study, total no. of skin biopsies received were 282, of which 5% were adnexal tumors. All the tissue speci- men received were formalin fixed, processed in paraffin wax, stained with Haematoxylin & Eosin along with special stains wherever necessary & reported. Among adnexal tumors, the tumors with eccrine differentiation constituted 50% & apocrine were 21.42%. Tumors with follicular differentiation were 21.42% & single case with sebaceous differentia- tion accounting to 7.14% . M:F ratio in benign tumors is 1:1, and 2 cases of malignant tumors in males are reported at ASRAMS. Clinically adnexal neoplasms should be regarded as precursor of malignancy. So critical evaluation of the skin biopsies is essential.
    [Show full text]
  • Chengalpattu Medical College, Chengalpattu
    1 CLINICO-PATHOLOGICAL STUDY OF CUTANEOUS TUMOURS OF HEAD AND NECK Dissertation Submitted in partial fulfillment of university regulations for M.D. DEGREE IN DERMATOLOGY, VENEREOLOGY AND LEPROSY BRANCH XX CHENGALPATTU MEDICAL COLLEGE, CHENGALPATTU THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY CHENNAI, TAMIL NADU APRIL 2011 2 CONTENTS S.NO. TITLE PAGE NO. 1. INTRODUCTION 1 2. REVIEW OF LITERATURE 3 3. AIMS AND OBJECTIVES OF THE STUDY 48 4. MATERIALS AND METHODS 49 5. OBSERVATIONS 51 6. DISCUSSION 66 7. CONCLUSION 72 APPENDICES REFERENCES PROFORMA MASTER CHART 3 INTRODUCTION Skin is a complex and the largest organ in the body. Because of its complexity a wide range of diseases can develop from the skin including tumors from surface epidermis, epidermal appendages , dermal & subcutaneous tissue. The vast diversity of these lesions combined with a body of descriptive data, often overlapping (clinical,histological) produces confusion in the area of nomenclature and difficulty in diagnosis. Tumours of skin are histopathologically diverse group of entities which have common localized proliferation of cells resulting in clinically discrete lesions. They may be divided into a number of categories, reflecting their different biological behaviour. These include hamartomas, benign tumours, premalignant and malignant conditions. This study of tumours of skin has been undertaken to find out the frequency of benign and malignant growths. The study has been limited to the cases attending the Dermatology Department, chengalpattu Government Hospital, chengalpattu. Most of the tumours whether benign or malignant are symptomless but are cosmetically unacceptable. The distinction between benign and malignant neoplasm are rather more difficult to define when they appear in skin than when found elsewhere and histopathological examination is frequently required to 4 establish a definitive diagnosis.
    [Show full text]
  • 21 Genodermatoses
    . 21 . 21.2 The Ichthyoses 21 Genodermatoses Although this chapter is devoted to genodermatoses, many acquired disorders are also considered when they seem to fit into the general clinical picture. For example, acquired forms of porokeratosis are considered along with the less common in- herited ones. Genodermatoses 21.1 MIM Code What..................................................................................... is the MIM Code? Victor A. McKusick, one of the giants of clinical human genetics, started using a numerical code when he began compiling his books entitled Mendelian Inheritance in Man. The books evolved into a website, OMIM (Online Mendelian Inheritance in Man), which today serves as the standard for clinical genetics and the most convenient way to acquire updated information on all genetic disorders. The MIM code is given throughout this book whenever it is relevant. The first digit identifies the pattern of diagnosis: 1 = autosomal dominant inheritance; 2 = auto- somal recessive inheritance; 3 = X-linked inheritance. .....................................................................................How to Use OMIM 1 Simply enter ONIM in Google or any search engine and you will land on OMIM—or enter www.ncbi.nlm.nih.gov/OMIM. 2 Search OMIM. 3 Enter the MIM code, or a key word or two if you are looking for a syndrome or set of findings. 4 You will see a list of disease descriptions likely to be relevant to your query; chose whichever ones seem most useful. 5 Now you can read an update about the disease, the gene, find extensive references, or be linked to Medline. 21.2 The Ichthyoses Overview..................................................................................... The primary ichthyoses are a heterogenous group of inherited disorders featuring ex- cessive scale.
    [Show full text]
  • Cosmetic and Pharmaceutical Compositions Comprising ACE Inhibitors And/Or Angiotensin II Receptor Antagonists for Treating Dermatological Disorders
    (19) & (11) EP 2 377 532 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.10.2011 Bulletin 2011/42 A61K 31/401 (2006.01) A61K 31/404 (2006.01) A61K 31/41 (2006.01) A61K 31/4164 (2006.01) (2006.01) (2006.01) (21) Application number: 11168684.6 A61K 31/4166 A61K 31/4174 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) (2006.01) (2006.01) (22) Date of filing: 18.08.2005 A61K 31/4245 A61K 31/47 A61K 31/472 (2006.01) A61K 31/502 (2006.01) A61K 31/554 (2006.01) A61K 38/06 (2006.01) A61K 38/05 (2006.01) A61P 17/00 (2006.01) A61P 17/06 (2006.01) A61P 17/02 (2006.01) A61P 35/00 (2006.01) A61K 38/07 (2006.01) A61K 38/08 (2006.01) (84) Designated Contracting States: (72) Inventor: Bonnichsen, Richard AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Victoria, Mahe (SC) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Høiberg A/S St. Kongensgade 59 A (30) Priority: 18.08.2004 DK 200401247 DK-1264 Copenhagen K (DK) 08.09.2004 US 607919 P Remarks: (62) Document number(s) of the earlier application(s) in This application was filed on 03-06-2011 as a accordance with Art. 76 EPC: divisional application to the application mentioned 05771000.6 / 1 789 031 under INID code 62. (71) Applicant: Ace ApS 3000 Helsingor (DK) (54) Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders (57) In one aspect, the present invention relates to taining the skin tone of an individual suffering from, or at use of an ACE inhibitor and/or angiotensin II receptor risk of suffering from, a dermatological disorder, said antagonist for the preparation of a medicament for the method comprising contacting the skin of said individual treatment of a dermatological disorder, particularly by with an ACE inhibitor and/or angiotensin II receptor an- topical application of said ACE inhibitor and/or angi- tagonist.
    [Show full text]
  • Current Management Approach to Hidradenocarcinoma: a Comprehensive Review of the Literature
    Current management approach to hidradenocarcinoma: a comprehensive review of the literature Abhishek Soni, Nupur Bansal, Vivek Kaushal and Ashok Kr Chauhan Department of Radiotherapy, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India Correspondence to: Abhishek Soni. Email: [email protected] Abstract Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials. Review Keywords: hidradenocarcinoma, management, wide local excision, radiotherapy Published: 19/03/2015 Received: 02/12/2014 ecancer 2015, 9:517 DOI: 10.3332/ecancer.2015.517 Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • JULY 2006 American Osteopathic College of Dermatology
    The Journal of the American PRSRT STD Osteopathic College of Dermatology U.S. POSTAGE PAID 3700 North 32nd Terrace MASON CITY, IA Hollywood, Fl 33201 PERMIT NO. 429 Address Correction Requested T HE J OURNAL OF THE A JOURNAL SPECIFICALLY FOR AND BY RESIDENTS IN DERMATOLOGY A MERICAN O STEOPATHIC C OLLEGE OF D ERMATOLOGY Accepting Manuscripts from Dermatology Residents in AOA and ACGME Approved Residency Programs J ULY 2006 FOUNDING SPONSORS:ALLERGAN SKIN CARE • CONNETICS CORPORATION • GLOBAL PATHOLOGY LABORATORY • MEDICIS • STIEFEL LABORATORIES Journal of the AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY Journal of the 2005-2006 Officers President: Richard A. Miller, DO President-Elect: Bill V. Way, DO American First Vice-President: Jay S. Gottlieb, DO Second Vice-President:Donald K. Tillman, DO Osteopathic Third Vice-President: Marc I. Epstein, DO Secretary-Treasurer: Jere J. Mammino, DO Immediate Past President: Ronald C. Miller, DO College Trustees: David W. Dorton, DO Bradley P. Glick, DO Daniel S. Hurd, DO of Dermatology Jeffrey N. Martin, DO Executive Director: Rebecca Mansfield, MA Editors Jay S. Gottlieb, D.O., F.O.C.O.O. Stanley E. Skopit, D.O., F.A.O.C.D. Founding Sponsors: James Q. Del Rosso, D.O., F.A.O.C.D. Allergan Skin Care Connetics Corporation Global Pathology Laboratory Medicis Stiefel Laboratories Editorial Review Board Ronald Miller, D.O. Eugene Conte, D.O. Evangelos Poulos, M.D. Stephen Purcell, D.O. AOCD • 1501 E. Illinois • Kirksville, MO 63501 Darrel Rigel, M.D. 800-449-2623 • FAX: 660-627-2623 www.aocd.org Robert Schwarze, D.O. Andrew Hanly, M.D.
    [Show full text]
  • Schamberg's Disease
    Journal of the American Osteopathic College of Dermatology Volume 12, Number 1 SPONSORS: ',/"!,0!4(/,/'9,!"/2!4/29s-%$)#)3 September 2008 34)%&%,,!"/2!4/2)%3s'!,$%2-! www.aocd.org Journal of the American Osteopathic College of Dermatology Journal of the American Osteopathic College of Dermatology 2007-2008 Officers President: Jay Gottlieb, DO President Elect: Donald Tillman, DO First Vice President: Marc Epstein, DO Second Vice President: Leslie Kramer, DO Third Vice President: Bradley Glick, DO Secretary-Treasurer: Jere Mammino, DO (2007-2010) Immediate Past President: Bill Way, DO Trustees: James Towry, DO (2006-2008) Mark Kuriata, DO (2007-2010) Karen Neubauer, DO (2006-2008) David Grice, DO (2007-2010) Sponsors: Global Pathology Laboratory Stiefel Laboratories Editors Medicis Jay S. Gottlieb, D.O., F.O.C.O.O. Stanley E. Skopit, D.O., F.A.O.C.D. Galderma Editorial Review Board Ronald Miller, D.O. JAOCD Eugene Conte, D.O. Founding Sponsor Evangelos Poulos, M.D. Stephen Purcell, D.O. Darrel Rigel, M.D. !/#$s%)LLINOISs+IRKSVILLE -/ s&!8 Robert Schwarze, D.O. WWWAOCDORG Andrew Hanly, M.D. #/092)'(4!.$0%2-)33)/.WRITTENPERMISSIONMUSTBEOBTAINED Michael Scott, D.O. FROMTHE*OURNALOFTHE!MERICAN/STEOPATHIC#OLLEGEOF$ERMATOLOGY FORCOPYINGORREPRINTINGTEXTOFMORETHANHALFPAGE TABLESORlGURES Cindy Hoffman, D.O. 0ERMISSIONSARENORMALLYGRANTEDCONTINGENTUPONSIMILARPERMISSION Charles Hughes, D.O. FROMTHEAUTHORS INCLUSIONOFACKNOWLEDGEMENTOFTHEORIGINALSOURCE ANDAPAYMENTOFPERPAGE TABLEORlGUREOFREPRODUCEDMATERIAL Bill Way, D.O. 0ERMISSIONFEESAREWAIVEDFORAUTHORSWISHINGTOREPRODUCETHEIROWN Daniel Hurd, D.O. ARTICLES2EQUESTFORPERMISSIONSHOULDBEDIRECTEDTO*!/#$CO!/#$ 0/"OX+IRKSVILLE -/ Mark Lebwohl, M.D. #OPYRIGHTBYTHE*OURNALOFTHE!MERICAN/STEOPATHIC#OLLEGEOF Edward Yob, D.O. $ERMATOLOGY Jere Mammino, D.O. Printed by: Stoyles Graphics Services, Mason City, IA 50401 Schield M. Wikas, D.O. Proofreading: Julia Layton, Freelance Proofreading and Editing Journal of the American Osteopathic College of Dermatology Iqbal A.
    [Show full text]
  • An Unusual Case of Multiple Grouped Non-Familial Trichoepitheliomas
    Volume 27 Number 5| May 2021 Dermatology Online Journal || Case Presentation 27(5):8 An unusual case of multiple grouped non-familial trichoepitheliomas Michelle Vy1 MD, Mehrnaz Mehrzad3 BA, Thomas Konia1 MD, Barbara Burrall1 MD Affiliations: 1Department of Dermatology, University of California Davis, Sacramento, California, USA, 2Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California, USA, 3School of Medicine, University of California Davis, Sacramento, California, USA Corresponding Author: Michelle Vy MD, 3301 C Street, Suite 1400, Sacramento, CA 95816, Tel: 916-734-6111, Email: [email protected] 32-year-old woman with a sporadic case of multiple Abstract trichoepitheliomas on the trunk. Extensive literature Trichoepitheliomas (TEs) are benign and rare adnexal review did not reveal any non-familial cases of non- hamartomas of the pilosebaceous units. segmental, but clustered, multiple Trichoepitheliomas could occur in the setting of an trichoepitheliomas. underlying genetic disorder with multiple TEs or as solitary non-hereditary TEs. We report a healthy 32- year-old woman with sporadic multiple clustered and non-segmental TEs without positive family Case Synopsis history. There have been two other cases reported in A 32-year-old woman presented with asymptomatic the literature that had non-familial multiple TEs, one multiple small skin-colored raised papules on her was facially disfiguring and the other was in a right upper back for about 15 years (Figure 1). The segmental pattern. Our case has been the only one lesions had been stable since first noticed and had reported in the English literature which has sporadic, not grown in size or number.
    [Show full text]